Mirk/dyrk1B kinase in ovarian cancer

International Journal of Molecular Sciences

Volumn 14, Issue 3, 2013, Pages 5560-5575

  Friedman, Eileen ^a  

^a State University of New York Upstate Medical University: College of Medicine   (United States)

Author keywords

Mirk dyrk1B; Quiescence; ROS control

Indexed keywords

CYCLIN D; CYCLIN DEPENDENT KINASE 4; EHT 5372; MINIBRAIN RELATED KINASE; PROTEIN SERINE THREONINE KINASE; PROTEIN SERINE THREONINE KINASE INHIBITOR; REACTIVE OXYGEN METABOLITE; RO 5454948; TRANSCRIPTION FACTOR FOXO; UNCLASSIFIED DRUG;

AMPLICON; ASCITES TUMOR; BIOACCUMULATION; CANCER CELL CULTURE; CELL CYCLE CHECKPOINT; CELL CYCLE G2 PHASE; CELL CYCLE M PHASE; CELL SURVIVAL; CELL VIABILITY; CHROMOSOME 6; DIPLOIDY; DRUG MECHANISM; ENZYME ACTIVATION; ENZYME ACTIVITY; ENZYME BINDING; ENZYME INHIBITION; ENZYME PHOSPHORYLATION; G0 PHASE CELL CYCLE CHECKPOINT; G1 PHASE CELL CYCLE CHECKPOINT; GENE; GENE AMPLIFICATION; GENE FUNCTION; HUMAN; IN VIVO STUDY; MINIBRAIN RELATED KINASE GENE; OVARY CANCER; PROTEIN EXPRESSION; REVIEW;

EID: 84875070249     PISSN: 16616596     EISSN: 14220067     Source Type: Journal    
DOI: 10.3390/ijms14035560     Document Type: Review

References (30)

1. Barnes, D.; Melo, J. Primitive, quiescent and difficult to kill: The role of non-proliferating stem cells in chronic myeloid leukemia. Cell Cycle 2006, 5, 2862-2866.
2. Hu, J.; Friedman, E. Depleting mirk kinase increases cisplatin toxicity in ovarian cancer cells. Genes Cancer 2010, 1, 803-811.
3. Janumyan, Y.; Cui, Q.; Yan, L.; Sansam, C.G.; Vanlentin, M.; Yang, E. G0 function of BCL2 and BCL-xL requires BAX, BAK, and p27 phosphorylation by Mirk, revealing a novel role of BAX and BAK in quiescence regulation. J. Biol. Chem. 2008, 283, 34108-34120
4. Lu, Z.; Luo, R.Z.; Lu, Y.; Zhang, X.; Yu, Q.; Khare, S.; Kondo, S.; Kondo, Y.; Yu, Y.; Mills, G.B.; et al. The tumor suppressor gene ARHI regulates autophagy and tumor dormancy in human ovarian cancer cells. J. Clin. Invest. 2008, 118, 3917-3929.
5. Amaravadi, R.K. Autophagy-induced tumor dormancy in ovarian cancer. J. Clin. Invest. 2008, 118, 3837-40.
6. Adam, A.P.; George, A.; Schewe, D.; Bragado, P.; Iglesias, B.V.; Ranganathan, A.C.; Kourtidis, A.; Conklin, D.S.; Aguirre-Ghiso, J.A. Computational identification of a p38SAPK-regulated transcription factor network required for tumor cell quiescence. Cancer Res. 2009, 69, 5664-5672
7. Chen, C.; Liu, Y.; Liu, R.; Ikenoue, T.; Guan, K.L.; Liu, Y.; Zheng, P. TSC-mTOR maintains quiescence and function of hematopoietic stem cells by repressing mitochondrial biogenesis and reactive oxygen species. J. Exp. Med. 2008, 205, 2397-2408.
8. Deng, X.; Ewton, D.Z.; Friedman, E. Mirk/Dyrk1B maintains the viability of quiescent pancreatic cancer cells by decreasing ROS levels. Cancer Res. 2009, 69, 3317-3324.
9. Jin, K.; Park, S.-J.; Ewton, D.; Friedman, E. The survival kinase Mirk/dyrk1B is a downstream effector of oncogenic K-ras. Cancer Res. 2007, 67, 7247-7255.
10. Collins, C.S.; Hong, J.; Sapinoso, L.; Zhou, Y.; Liu, Z.; Micklash, K.; Schultz, P.G.; Hampton, G.M. A small interfering RNA screen for modulators of tumor cell motility identifies MAP4K4 as a promigratory kinase. PNAS 2006, 103, 3775-3780.
11. Thompson, F.H.; Nelson, M.A.; Trent, J.M.; Guan, X.Y.; Liu, Y.; Yang, J.M.; Emerson, J.; Adair, L.; Wymer, J.; Balfour, C.; et al. Amplification of 19q13.1-q13.2 sequences in ovarian cancer: G-band, FISH, and molecular studies. Cancer Gene. Cytogenet. 1996, 87, 55.
12. Cancer Genome Atlas Research Network. Integrated genomic analyses of ovarian carcinoma. Nature 2011, 474, 609-615.
13. Kuuselo, R.; Savinainen, K.; Azorsa, D.O.; Basu, G.D.; Karhu, R.; Tuzmen, S.; Mousses, S.; Kallioniemi, A. Intersex-like (IXL) is a cell survival regulator in pancreatic cancer with 19q13 amplification. Cancer Res. 2007, 67, 1943-1949.
14. Cheng, J.Q.; Godwin, A.K.; Bellacosa, A.; Taguchi, T.; Franke, T.F.; Hamilton, T.C.; Tsichlis, P.N.; Testa, J.R. AKT2, a putative oncogene encoding a member of a subfamily of protein-serine/threonine kinases, is amplified in human ovarian carcinomas. PNAS 1992, 89, 9267-9271.
15. Hu, J.; Nakhla, H.; Friedman, E. Transient arrest in a quiescent state allows ovarian cancer cells to survive suboptimal growth conditions and is mediated by Mirk/dyrk1B and p130/Rb2. Int. J. Cancer 2011, 129, 307-318.
16. Lee, K.; Deng, X.; Friedman, E. Mirk protein kinase is a mitogen-activated protein kinase substrate that mediates survival of colon cancer cells. Cancer Res. 2000, 60, 3631-3637.
17. Gao, J.; Yang, X.; Yin, P.; Hu, W.; Liao, H.; Miao, Z.; Pan, C.; Li, N. The involvement of FoxO in cell survival and chemosensitivity mediated by Mirk/Dyrk1B in ovarian cancer. Int. J. Oncol. 2012, 40, 1203-1209.
18. Deng, X.; Mercer, S.E.; Shah, S.; Ewton, D.Z.; Friedman, E. The cyclin-dependent kinase inhibitor p27Kip1 is stabilized in G0 by mirk/dyrk1B kinase. J. Biol. Chem. 2004, 279, 22498-22504.
19. Zou, Y.; Ewton, D.; Deng, D.; Mercer, S.; Friedman, E. Mirk/dyrk1B kinase destabilizes cyclin D1 by phosphorylation at threonine 288. J. Biol. Chem. 2004, 279, 27790-27798.
20. Becker, W. Emerging role of DYRK family protein kinases as regulators of protein stability in cell cycle control. Cell Cycle 2012, 11, 3389-3394.
21. Litovchick, L.; Florens, L.A.; Swanson, S.K.; Washburn, M.P.; DeCaprio, J.A. DYRK1A protein kinase promotes quiescence and senescence through DREAM complex assembly. Genes Dev. 2011, 25, 801-813.
22. Deng, X.; Ewton, D.Z.; Pawlikowski, B.; Maimone, M.; Friedman, E. Mirk/dyrk1B is a Rho-induced kinase active in skeletal muscle differentiation. J. Biol. Chem. 2003, 278, 41347-41354.
23. Mercer, S.E.; Ewton, D.Z.; Deng, X.; Lim, S.; Mazur, T.R.; Friedman, E. Mirk/dyrk1B mediates survival during the differentiation of C2C12 myoblasts. J. Biol. Chem. 2005, 280, 25788-257801.
24. Gao, J.; Zhao, Y.; Lv, Y.; Chen, Y.; Wei, B.; Tian, J.; Yan, Z.; Kong, F.; Pang, J.; Liu, J.; et al. Mirk/Dyrk1B mediates G0/G1 to S phase cell cycle progression and cell survival involving MAPK/ERK signaling in human cancer cells. Cancer Cell Int. 2013, 13, 2.
25. Coller, H.; Sang, L.; Roberts, J.M. A new description of cellular quiescence. PLoS Biol. 2006, 4, 329-349.
26. Smith, E.; Leone, G.; Nevins, J. Distinct mechanisms control the accumulation of the Rb-related p107 and p130 proteins during cell growth. Cell Growth Diff. 1998, 9, 297-303.
27. D'Andrilli, G.; Masciullo, V.; Bagella, L.; Tonini, T.; Minimo, C.; Zannoni, G.F.; Giuntoli, R.L., II; Carlson, J.A., Jr.; Soprano, D.R.; Soprano, K.J.; et al. Frequent loss of pRb2/p130 in human ovarian carcinoma. Clin. Cancer Res. 2004, 10, 3098-3103.
28. Hu, J.; Deng, H.; Friedman, E. Ovarian cancer cells, not normal cells, are damaged by mirk/dyrk1B kinase inhibition. Int. J. Cancer 2013, doi:10.1002/ijc.27917.
29. Correa, R.J.M.; Peart, T.; Valdes, Y.R.; DiMattia, G.E.; Shepherd, T.G. Modulation of AKT activity is associated with reversible dormancy in ascites-derived epithelial ovarian cancer spheroids. Carcinogenesis 2012, 33, 49-58.
30. Leder, S.; Czajkowska, H.; Maenz, B.; de Graaf, K.; Barthel, A.; Joost, H.-G.; Becker, W. Alternative splicing variants of dual specificity tyrosine phosphorylated and regulated kinase 1B exhibit distinct patterns of expression and functional properties. Biochem. J. 2003, 372, 881-888.